Sostravel.com receives a research report by Arrowhead detailing a 2.76x potential upside in price
17.11.2022 10:00:00 EET | Business Wire | Press release
Sostravel.com S.p.A. (Euronext Growth Milan, ticker: SOS), digital operator offering booking services, digital itineraries including information on flights and airports, car rental, experiences, and proprietary services including the Lost Luggage Concierge through the Sostravel and Flio apps, as well as through the platforms www.Sostravel.com and www.amareitalia.com, announces that today, Arrowhead, an Independent Research company based in New York, providing due diligence and valuation reports on selected listed companies, published a research report on Sostravel, with a Fair Share Valuation Bracket of 2.01 to 2.50 EUR, when the share price of the company (ticker BIT: SOS) trades at ~0.90 EUR, for a 2,760% potential appreciation.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20221115006003/en/
Sostravel App offers booking services, digital itineraries including flight and airport information, car renting, experiences, and insurance services. The company operates the Lost Luggage Concierge proprietary service and is expanding into telehealth services designed for travellers. (Graphic: Business Wire)
Sostravel.com S.p.A. (SOS), headquartered in Italy, operates in the global travel and tourism (T&T) industry. It has a presence online, on Google Play, and Apple App Store, and in 23 airports in Europe, America, and Asia. The company was founded in 2017 as a spin-off from TraWell Co. (previously Safe Bag).
On November 1st, the company finalized the merger with DDC, a company with strong expertise in digital marketing for traveling and an established booking platform. The app, now merged with DDC allows customers to engage in bookings of airplanes, hotels, and cars, build a digital itinerary with other services, such as tours and events, and access value-added services like Lost Luggage Concierge and telehealth. The strategy is to attract potential customers with booking services and offer high-margin services through the app, focusing on the leisure and holiday segments.
The new post-merger entity is positioned to capture the growth in digital travel revenues, already owning a significant share of the passenger information sector, Sostravel aims to consolidate the world of traveler information and services, with the only integrated app on the market.
Based on its due diligence and valuation estimates, Arrowhead believes that SOS’s fair share value lies in the EUR 2 to EUR 2.50 bracket, which has been calculated using a blended valuation method: with 60% weighting to a discounted cash flow (DCF) method and 40% weighting to a Comparable Companies Valuation method.
Sostravel is listed on Euronext Growth Milan, ticker BIT: SOS
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20221115006003/en/
Contact information
For further information:
Sostravel.com S.p.A.
Investor Relations
Edoardo Zarghetta
investor.relations@Sostravel.com
www.Sostravel.com
Ph: +39 0331 1587117
Fax: +39 0331 1582452
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Brenus Pharma Announces FDA Acceptance of IND Application for STC-1010 (BreAK-CRC001) in MSS Metastatic Colorectal Cancer (mCRC)27.5.2026 09:49:00 EEST | Press release
Brenus Pharma, a clinical stage biotechnology company developing novel in vivo immunotherapies for solid tumors, announced that the U.S. Food and Drug Administration (FDA) has accept the company's Investigational New Drug (IND) application for its first drug candidate, STC-1010, in microsatellite stable (MSS) metastatic colorectal cancer (mCRC). STC-1010 is designed to address a critical unmet need worldwide. Approximately 95% of mCRC patients have MSS tumors, which demonstrate minimal response to standard immunotherapies. The FDA validated Brenus Pharma's advanced regulatory and manufacturing capabilities. This operational readiness will accelerate patient access and data generation across both European and US sites for a Phase II program planned for 2027. "FDA's acceptance of our IND represents a major validation of our program and enables the full execution of our clinical strategy across Europe and the United States. Achieving regulatory alignment across multiple jurisdictions refl
Alfasigma presents first data on filgotinib from the Phase 3 OLINGUITO trial in axial spondyloarthritis at EULAR 202627.5.2026 09:00:00 EEST | Press release
Alfasigma S.p.A, a global pharmaceutical company with a focus on innovation in rare and specialty care where there is significant unmet patient need, presented positive results from the OLINGUITO Phase 3 clinical trial (NCT05785611iEudraCT 2022-501354-10-01ii) at EULAR 2026. In OLINGUITO filgotinib, an oral, once-daily JAK1 preferential inhibitor under investigation for the treatment of adult patients with active axial spondyloarthritis (axSpA), demonstrated sustained improvements in the signs and symptoms of axSpA, including disease activity and inflammation.iii Safety was consistent with the known profile of filgotinib, indicating a favourable benefit-risk profile for patients with active axSpA.iii The OLINGUITO trial consists of two international, randomised, double-blind, placebo-controlled studies (Study A and Study B), evaluating the efficacy and safety of filgotinib 200mg once-daily vs. placebo in patients with an established diagnosis of axSpA as per ASAS classification.i Eligi
Tide Crosses 2 Million Members Worldwide - Big Step Forward in Mission to Support and Grow Small Businesses27.5.2026 09:00:00 EEST | Press release
Tide, the UK’s leading business management platform, today announces it has crossed 2 million members globally, with India in particular seeing strong growth. More than 1.1 million small businesses joined Tide in India since the company launched there in December 2022. This makes India Tide’s fastest-growing market by member acquisition. The UK is Tide’s home market, with 900,000 SMEs, 15% market share, and the majority of the company’s revenue. Tide’s steadily expanding its presence in Europe, with Germany and France, where the platform is gaining strong traction, thanks to millions of small businesses turning to digital to manage their businesses. In late 2025, Tide received a strategic investment from TPG, a leading global alternative asset manager, valuing the company at $1.5 billion. Oliver Prill, CEO of Tide, said: “We are delighted to be crossing the 2 million member milestone. This number is a testament to the trust that our members place in us in all our markets. Behind every
Royal London Asset Management Expands Relationship with SS&C to Service New Australian Funds27.5.2026 01:00:00 EEST | Press release
SS&C Technologies Holdings, Inc. (Nasdaq: SSNC) today announced that Royal London Asset Management, a leading U.K. fund management company, has extended its relationship with SS&C. SS&C Global Investor & Distribution Solutions will provide fund administration and unit registry services for its new range of Australian active funds, including: Royal London Global Equity Diversified Fund Royal London Global Equity Enhanced Fund Royal London Global Equity Select Fund Royal London Short Duration Global High Yield Bond Fund RLAM is part of Royal London, the U.K.’s largest mutual life, pensions and investment company. SS&C services approximately £72bn in assets under management across its U.K. fund range. Equity Trustees will serve as the Responsible Entity for RLAM’s new funds, which have launched with around AUD $1 billion in AUM. The unit trusts are structured as feeder funds, providing investors with indirect exposure to RLAM’s range of Dublin-domiciled Undertakings for Collective Investm
SLB Announces Date for Second-Quarter 2026 Results Conference Call26.5.2026 20:00:00 EEST | Press release
SLB (NYSE: SLB) will hold a conference call on July 24, 2026, to discuss the results for the second quarter ending June 30, 2026. The conference call is scheduled to begin at 9:30 a.m. U.S. Eastern time and a press release regarding the results will be issued at 7:00 a.m. U.S. Eastern time. To access the conference call, listeners should contact the Conference Call Operator at +1 (800) 715-9871 within North America or +1 (646) 307-1963 outside of North America approximately 10 minutes prior to the start of the call and the access code is 3440360. A webcast of the conference call will be broadcast simultaneously at https://events.q4inc.com/attendee/157027565 on a listen-only basis. Listeners should log in 15 minutes prior to the start of the call to test their browsers and register for the webcast. Following the end of the conference call, a replay will be available at www.slb.com/irwebcast until July 31, 2026, and can be accessed by dialing +1 (800) 770-2030 within North America or +1
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom